Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis

doi:10.19439/j.sjos.2018.01.023

Abstract

Abstract: PURPOSE: To determine the prognostic role of high PD-L1 in patients with oral squamous cell carcinoma. METHODS: Electronic databases, such as PubMed, Embase and Cochrane library, were searched to identify studies evaluating PD-L1 expression and overall survival (OS) in these patients. RevMan 5.3 software was used for meta-analysis. RESULTS: A total of 12 studies that involved 1595 patients were included. Pooled hazard ratio (HR) 1.02 (95%CI= 0.93-1.11,P=0.71) indicated that the association between PD-L1 expression and overall survival (OS) was not significant. The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with gender (OR=0.64, 95%CI=0.48-0.85, P=0.002), differentiation (OR=0.58, 95%CI=0.37-0.90, P=0.01) and HPV infection (OR=1.91, 95%CI=1.13-3.23, P=0.02). However, PD-L1 had no correlation with tumour size, and lymph node status. CONCLUSIONS: PD-L1 expression may not be an independent predictor of prognosis of patients with OSCC. Well-designed large cohort studies are needed to confirm these findings.

Key words: OSCC, PD-L1, HPV, PD-1, Meta analysis

CLC Number:

R739.8

ZOU Bo, XU Kai, LIU Xian-bin, FAN Qing-chun, LIU Jian-lin, YUAN Dao-ying. Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis[J]. Shanghai Journal of Stomatology, 2018, 27(1): 100-105.

References

[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Marcus B, Arenberg D, Lee J, et al.Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma[J]. Cancer, 2004, 101(12): 2779-2787.
[3] Leemans CR, Braakhuis BJ, Brakenhoff RH.The molecular biology of head and neck cancer[J]. Nat Rev Cancer, 2011, 11(1): 9-22.
[4] Chin D, Boyle GM, Williams RM, et al.Novel markers for poor prognosis in head and neck cancer[J]. Int J Cancer, 2005, 113(5): 789-797.
[5] Zou W, Wolchok JD, Chen L.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations[J]. Sci Transl Med, 2016, 8(328): 324-328.
[6] Hansen JD, Du Pasquier L, Lefranc MP.et al.The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective[J]. Mol Immunol, 2009, 46(3): 457-472 .
[7] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264 .
[8] Sanmamed MF, Chen L.Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation[J]. Cancer J, 2014, 20(4): 256-261.
[9] Cierna Z, Mego M, Miskovska V, et al.Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors[J]. Ann Oncol, 2016, 27(2): 300-305.
[10] Wu P, Wu D, Li L, et al.PD-L1 and survival in solid tumors: a meta-analysis[J]. PLoS One, 2015, 10(6): e0131403.
[11] Chowdhury S, Veyhl J, Jessa F, et al.Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J]. Oncotarget, 2016, 7(22): 32318-32328.
[12] Cierna Z, Mego M, Miskovska V, et al.Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors[J]. Ann Oncol, 2016, 27(2): 300-305.
[13] Katsuya Y, Fujita Y, Horinouchi H, et al.Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma[J]. Lung Cancer, 2015, 88(2): 154-159.
[14] Zheng P, Zhou Z.Human cancer immunotherapy with PD-1/PD-L1 blockade[J]. Biomark Cancer, 2015, 7(Suppl 2): 15-18.
[15] Straub M, Drecoll E, Pfarr N, et al.CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity[J]. Oncotarget, 2016, 7(11): 12024-12034.
[16] Cho YA, Yoon HJ, Lee JI, et al.Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma[J]. Oral Oncol, 2011, 47(12): 1148-1153.
[17] Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605.
[18] Parmar MK, Torri V, Stewart L.Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J]. Stat Med, 1998, 17(24): 2815-2834.
[19] Troeltzsch M, Woodlock T, Pianka A, et al.Is there evidence for the presence and relevance of the pd-1/pd-l1pathway in oral squamous cell carcinoma? Hints from an immunohistochemical study[J]. J Oral Maxillofac Surg, 2017, 75(5): 969-977.
[20] Lin YM, Sung WW, Hsieh MJ, et al.High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma[J]. PLoS One, 2015, 10(11): e0142656.
[21] Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells[J]. Oncotarget, 2015, 6(25): 20902-20920.
[22] Lyford-Pike S, Peng S, Young GD, et al.Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma[J]. Cancer Res, 2013, 73(6): 1733-1741.
[23] Badoual C, Hans S, Merillon N, et al.PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer[J]. Cancer Res, 2013, 73(1): 128-138.
[24] Ukpo OC, Thorstad WL, Lewis JS Jr.B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma[J]. Head Neck Pathol, 2013, 7(2): 113-121.
[25] Satgunaseelan L, Gupta R, Madore J, et al.Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype[J]. Pathology, 2016, 48(6): 574-580.
[26] Chen TC, Wu CT, Wang CP, et al.Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof[J]. Oral Oncol, 2015, 51(11): 1004-1010.
[27] Ock CY, Kim S, Keam B, et al.PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma[J]. Oncotarget, 2016, 7(13): 15901-15914.
[28] Kim HS, Lee JY, Lim SH, et al.Association between PD-L1 and HPV status and the prognostic value of pd-l1 in oropharyngeal squamous cell carcinoma[J]. Cancer Res Treat, 2016, 48(2): 527-536.
[29] Jin Y, Zhao J, Shi X, et al.Prognostic value of programed death ligand 1 in patients with solid tumors: a meta-analysis[J]. J Cancer Res Ther, 2015, 11(Suppl 1): C38-43 .
[30] Karim R, Jordanova ES, Piersma SJ, et al.Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma[J]. Clin Cancer Res, 2009, 15(20): 6341-6347.
[31] Zhang M, Dong Y, Liu H, et al.The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1901 patients[J]. Sci Rep, 2016, 6: 37933.
[32] Ghebeh H, Lehe C, Barhoush E, et al.Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule[J]. Breast Cancer Res, 2010, 12(4): R48.